AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB

Primary objectives: To compare the progression-free-survival of second-line chemotherapy with Bevacizumab to second-line chemotherapy alone in patients treated with first-line chemotherapy + Bevacizumab.
Primary endpoints: progression-free-survival